ATIM-25. PD-1 INHIBITION CAN BE COMBINED WITH IL-12 IN SUBJECTS WITH RECURRENT GLIOBLASTOMA

Monotherapy with intratumoral Ad-RTS-hIL-12 (Ad), a novel gene therapeutic conditionally expressing IL-12 under the transcriptional control of oral veledimex (V, 20 mg) acting via the proprietary RheoSwitch Therapeutic System® (RTS®), was shown in a phase 1 Main study (NCT02026271) to elicit a susta...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Chiocca, Ennio, Lukas, Rimas, Rao, Ganesh, Buck, Jill, Demars, Nathan, Smith, Amy, Miao, John, Zhou, John, Gelb, Arnold, Cooper, Laurence
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Adult Clinical Trials–Immunologic
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847446/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.024
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki